Applied dna sciences inc (APDN)
Balance Sheet / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14Dec'13Sep'13Jun'13Mar'13Dec'12Sep'12Jun'12Mar'12Dec'11Sep'11Jun'11Sep'10
ASSETS
Current assets:
Cash and cash equivalents

8,662

8,662

558

507

1,541

3,137

1,659

2,514

3,709

4,764

2,959

2,402

4,020

6,701

4,479

7,086

9,785

12,382

7,312

10,730

984

2,871

1,393

2,025

1,988

4,199

6,360

1,831

4,405

984

724

1,256

856

1,935

2,747

-

-

Cash and cash equivalents

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

12

17

Accounts receivable, net of allowance of $4,500 at March 31, 2020 and September 30, 2019, respectively

549

273

839

243

316

614

1,485

1,414

1,525

2,155

2,587

4,746

5,192

6,156

6,374

4,792

5,026

3,923

3,929

2,077

1,160

1,114

834

518

605

749

672

587

407

361

296

442

323

232

208

177

63

Stock subscriptions receivable

-

-

-

-

-

-

-

-

-

-

-

505

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Inventories

88

82

142

309

314

225

221

295

293

314

326

376

353

323

297

126

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Prepaid expenses and other current assets

678

618

604

544

591

622

635

602

575

540

366

113

182

133

200

136

126

187

293

209

155

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Prepaid expenses and other current assets

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

149

135

170

108

126

174

141

25

52

80

107

23

49

76

102

161

Total current assets

9,979

9,637

2,146

1,604

2,763

4,600

4,002

4,827

6,104

7,774

6,241

8,143

9,749

13,314

11,351

12,142

14,939

16,494

11,535

13,017

2,299

4,135

2,363

2,714

2,702

5,075

7,207

2,561

4,838

1,398

1,101

1,806

1,203

2,218

3,032

292

242

Property and equipment, net

265

184

226

265

315

369

419

535

550

500

523

589

672

723

792

805

879

561

572

526

587

520

576

649

647

716

695

664

198

189

210

127

121

81

89

0

3

Other assets:
Deferred offering costs

-

-

109

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

287

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Long term accounts receivables

-

-

-

-

-

-

-

-

-

-

-

-

1,044

920

1,535

360

-

1,500

1,500

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Deposits

76

62

62

62

62

62

62

62

62

62

61

61

61

61

61

61

58

58

62

52

61

61

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Deposits

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

57

55

57

51

51

51

36

36

36

36

36

35

23

23

8

Deferred offering costs

-

-

-

-

-

-

-

-

-

-

-

-

0

-

13

-

-

-

-

-

-

-

181

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Goodwill

285

285

285

285

285

285

285

285

285

285

285

285

285

285

285

285

285

285

285

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Capitalized finance costs-net of accumulated amortization of $1,892,236 and $1,806,261, respectively

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

3

85

213

522

Patents, net of accumulated amortization of $34,257 (Note B)

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

0

0

0

Intangible assets, net

720

702

734

767

799

831

864

896

930

986

1,042

1,342

1,403

1,464

1,525

1,563

1,549

1,584

1,598

525

389

304

327

351

374

397

420

564

-

-

0

-

90

181

272

363

636

Total Assets

11,326

10,871

3,564

2,985

4,226

6,148

5,633

6,607

7,933

9,608

8,153

10,422

13,216

16,769

15,565

15,218

17,711

20,484

15,554

14,123

3,626

5,022

3,506

3,771

3,782

6,240

8,374

3,840

5,073

1,624

1,348

1,970

1,452

2,521

3,503

893

1,413

LIABILITIES AND EQUITY (DEFICIT)
Current liabilities:
Accounts payable and accrued liabilities (including related party of $40,000 at March 31, 2020)

1,178

1,053

1,616

1,171

1,014

1,357

965

818

1,022

1,127

944

1,730

1,896

2,201

2,247

2,184

2,633

2,110

2,385

1,418

1,443

1,197

1,494

1,259

1,319

1,209

966

1,533

809

808

592

378

388

787

768

1,316

967

Deferred revenue

671

455

628

-

-

-

1,856

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Promissory notes payable, including $1,000,000 with a related party at September 30, 2014

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

1,800

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Deferred revenue

-

-

-

802

1,205

1,375

-

2,298

1,204

342

351

674

1,325

1,791

1,837

848

50

57

282

204

227

524

583

348

415

324

148

-

-

-

-

25

-

-

-

-

-

Advances from Officers (Note E)

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

600

50

Convertible notes payable, net of unamortized discount of $541,120 (Note D)

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

250

250

3,088

3,730

2,951

1,774

Total current liabilities

1,849

1,508

2,245

1,973

2,219

2,733

2,821

3,116

-

-

1,295

2,404

3,221

3,992

4,084

3,032

2,683

2,168

2,667

1,623

1,671

1,721

3,878

1,608

1,735

1,534

1,115

1,533

809

808

592

653

638

3,875

4,498

4,868

2,791

Long term accrued liabilities

722

659

621

584

546

508

470

433

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Secured convertible notes payable, related party. net of debt issuance costs

1,485

1,479

1,442

2,215

2,194

2,141

1,586

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Secured convertible notes payable, recorded at fair value

-

-

102

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Long term accounts payable

-

-

-

-

-

-

-

-

-

-

-

-

141

127

215

-

-

320

320

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Long term deferred revenue

-

-

-

-

-

-

-

-

-

-

-

-

563

468

900

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Warrant liability

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

1,096

1,851

2,367

2,823

2,643

-

-

-

-

-

-

-

-

-

-

Total liabilities

4,058

3,647

4,413

4,773

4,960

5,382

4,879

3,549

2,226

1,470

1,295

2,404

3,926

4,587

5,200

3,032

2,683

2,488

2,987

1,623

1,671

1,721

4,974

3,459

4,102

4,358

3,758

-

-

-

592

-

-

-

-

-

-

Convertible note payable-related party, net of unamortized discount of $5,286

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

219

Commitments and contingencies

-

-

-

-

-

-

-

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

-

-

0

0

0

0

0

0

0

Applied DNA Sciences, Inc. Stockholders' Equity (Deficit):
Preferred stock, par value $0.001 per share; 10,000,000 shares authorized; -0- shares issued and outstanding as of March 31, 2020 and September 30, 2019, respectively

-

-

-

-

-

-

-

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

-

-

-

-

-

-

0

-

0

0

Common stock, par value $0.001 per share; 500,000,000 shares authorized; 4,059,943 and 1,207,993 shares issued and outstanding as of March 31, 2020 and September 30, 2019, respectively

4

3

1

38

37

35

0

30

30

30

27

27

26

26

24

24

24

24

21

21

17

17

-

-

-

-

-

-

-

-

-

-

-

513

-

352

346

Warrant liability

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

8,033

7,513

-

-

-

-

-

-

-

Preferred stock, value

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

0

0

0

-

0

-

-

Common stock, par value $0.001 per share; 500,000,000 and 1,350,000,000 shares authorized; 21,504,578 and 13,935,954 shares issued and outstanding as of September 30, 2015 and 2014, respectively

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

13

827

808

807

786

733

684

656

646

626

591

-

473

-

-

Additional paid in capital

269,693

266,699

255,962

253,444

253,021

251,837

249,119

247,918

247,680

247,965

243,503

242,808

240,472

239,934

234,158

233,564

233,038

232,539

224,186

223,623

211,412

210,872

198,277

197,138

194,606

194,059

190,523

-

176,384

170,356

-

167,929

166,032

162,399

160,387

153,112

149,396

Stock subscription receivable

-

-

-

-

-

-

-

-

-

-

-

-1,000

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Additional paid in capital

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

184,549

-

-

169,117

-

-

-

-

-

-

Accumulated deficit

-262,423

-259,471

-256,805

-255,271

-253,793

-251,107

-248,366

-244,890

-242,003

-239,856

-236,673

-233,818

-231,207

-227,778

-223,817

-221,402

-218,035

-214,567

-211,641

-211,145

-209,474

-207,588

-199,760

-197,654

-195,735

-192,985

-186,693

-182,975

-180,839

-177,711

-169,007

-167,239

-165,810

-164,266

-161,856

-157,439

-151,341

Applied DNA Sciences, Inc. stockholders' equity (deficit):

7,274

7,231

-841

-1,788

-734

766

754

3,058

5,707

8,138

6,858

8,017

9,290

12,181

10,365

12,185

15,027

17,995

12,566

12,499

1,955

3,300

-1,468

311

-320

1,882

4,616

2,307

-3,770

-6,698

756

1,316

813

-1,353

-995

-

-1,598

Noncontrolling interest

-5

-7

-7

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Total equity (deficit)

7,268

7,224

-848

-

-

-

754

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-3,974

-

Total liabilities and equity (deficit)

11,326

10,871

3,564

2,985

4,226

6,148

5,633

6,607

7,933

9,608

8,153

10,422

13,216

16,769

15,565

15,218

17,711

20,484

15,554

14,123

3,626

5,022

3,506

3,771

3,782

6,240

8,374

3,840

5,073

1,624

1,348

1,970

1,452

2,521

3,503

893

1,413